Features | Partner Sites | Information | LinkXpress
Sign In
Bio-Rad Diabetes Division
AB Sciex
FOCUS DIAGNOSTICS, INC.

New Rapid Diagnostic Test Developed for Antibiotics Resistance

By Labmedica International staff writers
Posted on 08 Jul 2014
Image: Scanning electron micrograph of multidrug resistant Acinetobacter baumannii, a non-fermentative aerobic Gram-negative rod (Photo courtesy of Bioquell).
Image: Scanning electron micrograph of multidrug resistant Acinetobacter baumannii, a non-fermentative aerobic Gram-negative rod (Photo courtesy of Bioquell).
A rapid diagnostic test for multiresistance to broad-spectrum antibiotics has been developed for multidrug-resistant strains of Acinetobacter baumannii, an important hospital pathogen.

Bacterial resistance to antibiotics has increased considerably over recent years and the situation is particularly dramatic in regard to Gram-negative bacilli such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and A. baumannii, found in septicemic and abdominal infections and infections of the urinary tract and the lungs.

Microbiologists at the University of Fribourg (Switzerland) and their colleagues at Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France) collected a total of 220 strains to evaluate the performance of the CarbAcineto NP test. The strains included a collection of 151 carbapenemase-producing and 69 non-carbapenemase-producing Acinetobacter spp.

The test is based on the acidification properties generated by the enzymatic hydrolysis of a carbapenem, imipenem, when it is cleaved by a carbapenemase. The medium acidifies and the acidity indicator, which indicates pH, then turns from red to yellow. The detection of this carbapenemase activity can be realized by testing already isolated bacteria or any site infections. The result is obtained in less than two hours, while other techniques currently available require a minimum of 24 hours, most frequently 72 hours.

The specificity and of the CarbAcineto NP test were found to be 100% and the sensitivity was 94.7%. The CarbAcineto NP test efficiently detected OXA-type carbapenemase producers, leading to a significant improvement of the sensitivity to 94.7% for the CarbAcineto NP test versus 11.9% for the original Carba NP test. The use of the CarbAcineto NP test will be particularly important for intensive care unit (ICU) patients, for whom multidrug-resistant isolates belonging to the A. baumannii-A. calcoaceticus complex are a common source of severe infections. It specifically makes sense to test for carbapenemase production considering that the acquisition of a carbapenemase in A. baumannii is a marker of multidrug resistance.

The authors concluded that the CarbAcineto NP test is simple, cost-effective and, by detecting multidrug-resistant strains, it can prevent them spreading via outbreaks of hospital infections caused by multidrug-resistant bacteria, particularly among the most seriously ill patients and those undergoing resuscitation. This new test also provides a guide in the choice between the very few remaining treatment options for infected patients. Inserm Transfert (Paris, France) have filed an international patent for the CarbAcineto NP test. The study was published in the May 2014 issue of the Journal of Clinical Microbiology.

Related Links:

University of Fribourg
Faculté de Médecine Paris-Sud 
Inserm Transfert



PURITAN MEDICAL
77 ELEKTRONIKA
DiagCor Bioscience
comments powered by Disqus
Sekisui Diagnostics

Channels

Clinical Chemistry

view channel
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).

Low Levels of Prohormone Predicts Coronary Heart Disease

The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.... Read more

Genetic Tests

view channel
Image: The BioMark HD and EP1 platform with Digital Array Integrated Fluidic Circuits for quantitative real-time polymerase chain reaction (Photo courtesy of Fluidigm).

Molecular Test Identifies Acute Transplant Rejection

The development of noninvasive molecular assays to improve disease diagnosis and patient monitoring is a critical need in renal transplantation, as acute rejection (AR) increases the risk for chronic graft... Read more

Pathology

view channel

Identification of Independent Primary Lung Tumors and Tumors with Metastases Using Next-Generation DNA Sequencing

A team of oncologists and surgeons used a next-generation DNA sequencing (NGS) technique to determine whether non-small-cell lung cancer patients with multiple tumors carried independent primary tumors or a single primary tumor that had metastasized. For patients with multiple tumors, distinguishing independent primary... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.